Simparica Trio


sarolaner / moxidectin / pyrantel embonate

This medicine is authorised for use in the European Union.


Simparica Trio is a veterinary medicine used to treat dogs with flea or tick infestations and roundworm or hookworm infections in the gut. At the same time, Simparica Trio is used to prevent heartworm and lungworm disease (both caused by blood worms that infect the heart and blood vessels supplying the lungs). It can also be used as part of a treatment for flea allergy dermatitis (an allergic reaction to flea bites). Simparica Trio contains the active substances sarolaner, moxidectin and pyrantel.

This EPAR was last updated on 16/07/2021

Authorisation details

Product details
Simparica Trio
Agency product number
Active substance
  • moxidectin
  • sarolaner
  • pyrantel embonate
International non-proprietary name (INN) or common name
  • sarolaner
  • moxidectin
  • pyrantel embonate
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Zoetis Belgium S.A.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Rue Laid Burniat, 1
1348 Louvain-la-Neuve

Product information

16/07/2021 Simparica Trio - EMEA/V/C/004846 - IB-0004

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

For dogs with, or at risk from, mixed external and internal parasitic infestations. The veterinary medicinal product is exclusively indicated when use against ticks or fleas and gastrointestinal nematodes is indicated at the same time. The veterinary medicinal product also provides concurrent efficacy for the prevention of heartworm disease and angiostrongylosis.


  • For the treatment of tick infestations. The veterinary medicinal product has immediate and persistent tick killing activity for 5 weeks against Ixodes hexagonus, Ixodes ricinus and Rhipicephalus sanguineus and for 4 weeks against Dermacentor reticulatus;
  • For the treatment of flea infestations (Ctenocephalides felis and Ctenocephalides canis). The veterinary medicinal product has immediate and persistent flea killing activity against new infestations for 5 weeks;
  • The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

Gastrointestinal nematodes

For the treatment of gastrointestinal roundworm and hookworm infections:

  • Toxocara canis immature adults (L5) and adults;
  • Ancylostoma caninum L4 larvae, immature adults (L5) and adults;
  • Toxascaris leonina adults;
  • Uncinaria stenocephala adults.

Other nematodes

  • For the prevention of heartworm disease (Dirofilaria immitis);
  • For the prevention of angiostrongylosis by reducing the level of infection with immature adult (L5) stages of Angiostrongylus vasorum.

Assessment history

Related content

How useful was this page?

Add your rating
3 ratings
1 rating
1 rating